Medicenna Therapeutics Corp. (MDNA.TO)
| Previous Close | 2.3700 |
| Open | 2.3100 |
| Bid | 2.2700 x N/A |
| Ask | 2.2800 x N/A |
| Day's Range | 2.2500 - 2.3500 |
| 52 Week Range | 0.2150 - 2.8900 |
| Volume | |
| Avg. Volume | 167,542 |
| Market Cap | 169.748M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR 2024 abstract was limited to on-going interim results whereas the ASCO 2024 abstract specified data from a completed phase 1 study that were not presented at AACR 2024. No other matters were raised by ASCO regarding any
- GlobeNewswire
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by wa
- GlobeNewswire
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement
